Barcelona, Spain, January 11, 2021 – Accure Therapeutics, a private translational R&D engine at clinical stage in the Central Nervous System (CNS) field, today announces the appointment of five world-class neurology experts to its scientific advisory board. They will help boost innovation and advocate for Accure Therapeutics, as the company drives the advancement of its clinical trials and the development of new treatments.
“We are proud and delighted with the appointment of our expert scientific advisory board members; each of whom is a highly experienced pioneer within his field of expertise. Their exceptional skills, talent and experience will help us to steer and refine the direction of our development. Their combined connections in academia and industry will help us establish instrumental partnerships,” said Pablo Villoslada, CSO of Accure Therapeutics.
Accure Therapeutics, a European company with an international mindset, already has in its portfolio three new chemical entities, potential disease-modifying drug candidates because they address key dysregulations in CNS biology, with the potential to accommodate more. It is one of the few EU companies that operate in an agnostic fashion on initial science to deliver new disease modifying drugs in CNS. The latest scientific advisory board appointments will strengthen the company’s vision and future plans.
The appointees are:
Prof. Stephen L. Hauser said “I am delighted to join Accure Therapeutics as a scientific advisory board member. The Accure team is fantastic, and the company is well-positioned to become a leader in CNS therapeutics. Disorders of the brain represent the next great area for growth in biotechnology. As scientific advisors, we will collectively address the largely unmet needs for disease modifying therapies and help position Accure for success in developing innovative drugs against serious brain disorders that affect more than one billion people worldwide.”
CNS disorders are a leading cause of disability and a major cause of deaths worldwide, with prevalence set to increase due to an aging population. The CNS pharmaceutical market exceeds $80 billion (€73bn) per year and sustained growth is expected over the coming years.[1]
Accure Therapeutics is a private translational R&D engine at clinical stage in the Central Nervous System (CNS) field. Based in Barcelona (Spain), it was launched in 2020 with a Series A funding led by Alta Life Sciences Spain I and supported by the Centre for Technological and Industrial Development (CDTI). This European company with an international mindset boasts a unique portfolio of three new chemical entity programs pursuing innovative targets – with potential to accommodate others. Accure aims to develop new disease modifying drugs to treat serious conditions such as optic neuritis, multiple sclerosis, Parkinson’s disease and epilepsy. With an experienced business and scientific team, Accure Therapeutics is one of the few companies that operate in an agnostic fashion on initial science to deliver cutting-edge drugs in CNS.
[1] https://www.grandviewresearch.com/industry-analysis/central-nervous-system-cns-therapeutic-market
